发明名称 Compositions and methods for treating pigmentary conditions and melanoma
摘要 A method of treating melanoma in a subject comprising administering an amount of SOX9 sufficient to treat melanoma is disclosed. A method of treating a hyperpigmentary condition in a subject comprising administering an amount of inhibitor of SOX9 activity sufficient to treat the condition is disclosed. A method of treating melanoma in a subject comprising administering an amount of SOX9 sufficient to treat melanoma is disclosed. A method of treating melanoma in a subject comprising increasing the amounts of retinoic acid and SOX9 in the subject by amounts sufficient to treat melanoma. A method of treating melanoma in a subject comprising administering an amount of prostaglandin D2 and retinoic acid sufficient to treat cancer is disclosed. A method of sensitizing a melanoma cell to RA comprising administering an amount of SOX9 sufficient to decrease PRAME expression is disclosed.
申请公布号 US8946291(B2) 申请公布日期 2015.02.03
申请号 US200813059219 申请日期 2008.08.15
申请人 The United States of America, as represented by the Secretary, Department of Health & Human Services 发明人 Hearing Vincent J.;Passeron Thierry
分类号 A61K31/203;A61K31/5575;A61P35/00;A61K38/17 主分类号 A61K31/203
代理机构 Swanson & Bratschun, L.L.C. 代理人 Swanson & Bratschun, L.L.C.
主权项 1. A method of treating melanoma in a subject by restoring the subject's melanoma cells' sensitivity to retinoic acid (RA), comprising administering to the subject i) prostaglandin D2 (PGD2) or a prostaglandin D2 (PGD2) receptor agonist and ii) retinoic acid (RA) or a retinoic acid receptor (RAR) agonist, wherein the prostaglandin D2 (PGD2) or the prostaglandin D2 (PGD2) receptor agonist is in an amount sufficient to increase SOX9 expression in the subject, thus restoring the subject's melanoma cells' sensitivity to retinoic acid (RA) or the retinoic acid receptor (RAR) agonist, and wherein the retinoic acid (RA) or retinoic acid receptor (RAR) agonist is in an amount sufficient, in combination with the prostaglandin D2 (PGD2) or the prostaglandin D2 (PGD2) receptor agonist, to induce proliferation arrest, differentiation, or apoptosis of melanoma cells, thus treating melanoma in the subject.
地址 Washington DC US